Literature DB >> 18593900

A syngeneic variance library for functional annotation of human variation: application to BRCA2.

Tomas Hucl1, Carlo Rago, Eike Gallmeier, Jonathan R Brody, Myriam Gorospe, Scott E Kern.   

Abstract

The enormous scope of natural human genetic variation is now becoming defined. To accurately annotate these variants, and to identify those with clinical importance, is often difficult to assess through functional assays. We explored systematic annotation by using homologous recombination to modify a native gene in hemizygous (wt/Deltaexon) human cancer cells, generating a novel syngeneic variance library (SyVaL). We created a SyVaL of BRCA2 variants: nondeleterious, proposed deleterious, deleterious, and of uncertain significance. We found that the null states BRCA2(Deltaex11/Deltaex11) and BRCA2(Deltaex11/Y3308X) were deleterious as assessed by a loss of RAD51 focus formation on genotoxic damage and by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Deltaex11/Y3308Y), BRCA2(Deltaex11/P3292L), and BRCA2(Deltaex11/P3280H) had wild-type function. A proposed phosphorylation site at codon 3291 affecting function was confirmed by substitution of an acidic residue (glutamate, BRCA2(Deltaex11/S3291E)) for the native serine, but in contrast to a prior report, phosphorylation was dispensable (alanine, BRCA2(Deltaex11/S3291A)) for BRCA2-governed cellular phenotypes. These results show that SyVaLs offer a means to comprehensively annotate gene function, facilitating numerical and unambiguous readouts. SyVaLs may be especially useful for genes in which functional assays using exogenous expression are toxic or otherwise unreliable. They also offer a stable, distributable cellular resource for further research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593900      PMCID: PMC2536704          DOI: 10.1158/0008-5472.CAN-07-6189

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  38 in total

1.  Role of BRCA2 in control of the RAD51 recombination and DNA repair protein.

Authors:  A A Davies; J Y Masson; M J McIlwraith; A Z Stasiak; A Stasiak; A R Venkitaraman; S C West
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

2.  BRCA2 is required for homology-directed repair of chromosomal breaks.

Authors:  M E Moynahan; A J Pierce; M Jasin
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

3.  Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions.

Authors:  Maria Kraakman-van der Zwet; Wilhelmina J I Overkamp; Rebecca E E van Lange; Jeroen Essers; Annemarie van Duijn-Goedhart; Ingrid Wiggers; Srividya Swaminathan; Paul P W van Buul; Abdellatif Errami; Raoul T L Tan; Nicolaas G J Jaspers; Shyam K Sharan; Roland Kanaar; Malgorzata Z Zdzienicka
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

4.  Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses.

Authors:  Manu Kohli; Carlo Rago; Christoph Lengauer; Kenneth W Kinzler; Bert Vogelstein
Journal:  Nucleic Acids Res       Date:  2004-01-02       Impact factor: 16.971

5.  BRCA1- and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II.

Authors:  Alejandro D Treszezamsky; Lisa A Kachnic; Zhihui Feng; Junran Zhang; Chake Tokadjian; Simon N Powell
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

6.  Thymic model for examining BRCA2 expression and function.

Authors:  Kristina G Flores; Kimberly A McAllister; Paula K Greer; Roger W Wiseman; Laura P Hale
Journal:  Mol Carcinog       Date:  2002-11       Impact factor: 4.784

7.  Novel genotoxicity assays identify norethindrone to activate p53 and phosphorylate H2AX.

Authors:  Eike Gallmeier; Jordan M Winter; Steven C Cunningham; Saeed R Kahn; Scott E Kern
Journal:  Carcinogenesis       Date:  2005-05-19       Impact factor: 4.944

8.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.

Authors:  Thomas S Frank; Amie M Deffenbaugh; Julia E Reid; Mark Hulick; Brian E Ward; Beth Lingenfelter; Kathi L Gumpper; Thomas Scholl; Sean V Tavtigian; Dmitry R Pruss; Gregory C Critchfield
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

9.  Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.

Authors:  Hiroyuki Konishi; Bedri Karakas; Abde M Abukhdeir; Josh Lauring; John P Gustin; Joseph P Garay; Yuko Konishi; Eike Gallmeier; Kurtis E Bachman; Ben Ho Park
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

10.  Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.

Authors:  Mary-Claire King; Joan H Marks; Jessica B Mandell
Journal:  Science       Date:  2003-10-24       Impact factor: 47.728

View more
  41 in total

Review 1.  Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.

Authors:  Rohit Prakash; Yu Zhang; Weiran Feng; Maria Jasin
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-04-01       Impact factor: 10.005

2.  Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.

Authors:  Amy Dréan; Chris T Williamson; Rachel Brough; Inger Brandsma; Malini Menon; Asha Konde; Isaac Garcia-Murillas; Helen N Pemberton; Jessica Frankum; Rumana Rafiq; Nicholas Badham; James Campbell; Aditi Gulati; Nicholas C Turner; Stephen J Pettitt; Alan Ashworth; Christopher J Lord
Journal:  Mol Cancer Ther       Date:  2017-06-15       Impact factor: 6.261

3.  Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genes.

Authors:  Soma Ghosh; Surojit Sur; Sashidhar R Yerram; Carlo Rago; Anil K Bhunia; M Zulfiquer Hossain; Bogdan C Paun; Yunzhao R Ren; Christine A Iacobuzio-Donahue; Nilofer A Azad; Scott E Kern
Journal:  Am J Pathol       Date:  2013-11-06       Impact factor: 4.307

4.  Genome annotation by shotgun inactivation of a native gene in hemizygous cells: application to BRCA2 with implication of hypomorphic variants.

Authors:  Soma Ghosh; Anil K Bhunia; Bogdan C Paun; Samuel F Gilbert; Urmil Dhru; Kalpesh Patel; Scott E Kern
Journal:  Hum Mutat       Date:  2015-02       Impact factor: 4.878

5.  Cockayne syndrome group B protein regulates DNA double-strand break repair and checkpoint activation.

Authors:  Nicole L Batenburg; Elizabeth L Thompson; Eric A Hendrickson; Xu-Dong Zhu
Journal:  EMBO J       Date:  2015-03-27       Impact factor: 11.598

Review 6.  The complexity of pancreatic ductal cancers and multidimensional strategies for therapeutic targeting.

Authors:  Scott E Kern; Chanjuan Shi; Ralph H Hruban
Journal:  J Pathol       Date:  2010-11-16       Impact factor: 7.996

7.  Functional evaluation of variants of unknown significance in the BRCA2 gene identified in genetic testing.

Authors:  Marie Heczkova; Eva Machackova; Peter Macinga; Eike Gallmeier; Monika Cahova; Julius Spicak; Milan Jirsa; Lenka Foretova; Tomas Hucl
Journal:  Cancer Biol Ther       Date:  2019-01-13       Impact factor: 4.742

8.  Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM).

Authors:  Hannah Carter; Josue Samayoa; Ralph H Hruban; Rachel Karchin
Journal:  Cancer Biol Ther       Date:  2010-10-01       Impact factor: 4.742

Review 9.  Functional assays for analysis of variants of uncertain significance in BRCA2.

Authors:  Lucia Guidugli; Aura Carreira; Sandrine M Caputo; Asa Ehlen; Alvaro Galli; Alvaro N A Monteiro; Susan L Neuhausen; Thomas V O Hansen; Fergus J Couch; Maaike P G Vreeswijk
Journal:  Hum Mutat       Date:  2013-12-03       Impact factor: 4.878

Review 10.  Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.

Authors:  Erik S Knudsen; Eileen M O'Reilly; Jonathan R Brody; Agnieszka K Witkiewicz
Journal:  Gastroenterology       Date:  2015-09-15       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.